• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

带有主动和安慰剂对照的删失时间事件数据的非劣效性试验的设计和半参数分析。

Design and semiparametric analysis of non-inferiority trials with active and placebo control for censored time-to-event data.

机构信息

Institut für Mathematische Stochastik, Georg-August-Universität Göttingen, Goldschmitdstraße 7, 37077, Göttingen, Germany.

出版信息

Stat Med. 2013 Aug 15;32(18):3055-66. doi: 10.1002/sim.5769. Epub 2013 Mar 18.

DOI:10.1002/sim.5769
PMID:23508697
Abstract

The clinical trial design including a test treatment, an active control and a placebo is called the gold standard design. In this paper, we develop a statistical method for planning and evaluating non-inferiority trials with gold standard design for right-censored time-to-event data. We consider both lost to follow-up and administrative censoring. We present a semiparametric approach that only assumes the proportionality of the hazard functions. In particular, we develop an algorithm for calculating the minimal total sample size and its optimal allocation to treatment groups such that a desired power can be attained for a specific parameter constellation under the alternative. For the purpose of sample size calculation, we assume the endpoints to be Weibull distributed. By means of simulations, we investigate the actual type I error rate, power and the accuracy of the calculated sample sizes. Finally, we compare our procedure with a previously proposed procedure assuming exponentially distributed event times. To illustrate our method, we consider a double-blinded, randomized, active and placebo controlled trial in major depression.

摘要

临床试验设计包括测试治疗、阳性对照和安慰剂,被称为金标准设计。在本文中,我们为右删失时间事件数据的金标准设计非劣效性试验制定了一种统计方法。我们同时考虑了失访和行政删失。我们提出了一种半参数方法,仅假设风险函数的比例性。特别是,我们开发了一种算法,用于计算最小总样本量及其在治疗组中的最优分配,以便在替代方案下针对特定参数组合达到所需的功效。为了进行样本量计算,我们假设终点呈威布尔分布。通过模拟,我们研究了实际的Ⅰ型错误率、功效和计算出的样本量的准确性。最后,我们将我们的方法与假设事件时间呈指数分布的先前提出的方法进行了比较。为了说明我们的方法,我们考虑了一项在重度抑郁症中的双盲、随机、阳性对照和安慰剂对照试验。

相似文献

1
Design and semiparametric analysis of non-inferiority trials with active and placebo control for censored time-to-event data.带有主动和安慰剂对照的删失时间事件数据的非劣效性试验的设计和半参数分析。
Stat Med. 2013 Aug 15;32(18):3055-66. doi: 10.1002/sim.5769. Epub 2013 Mar 18.
2
The assessment of non-inferiority in a gold standard design with censored, exponentially distributed endpoints.在具有删失指数分布终点的金标准设计中进行非劣效性评估。
Stat Med. 2008 Nov 10;27(25):5093-110. doi: 10.1002/sim.3348.
3
Study duration for three-arm non-inferiority survival trials designed for accrual by cohorts.针对按队列进行病例积累设计的三臂非劣效性生存试验的研究持续时间。
Stat Methods Med Res. 2018 Feb;27(2):507-520. doi: 10.1177/0962280216633908. Epub 2016 Mar 17.
4
On the three-arm non-inferiority trial including a placebo with a prespecified margin.在三臂非劣效试验中,包括一个有预设边界的安慰剂。
Stat Med. 2011 Feb 10;30(3):224-31. doi: 10.1002/sim.4099. Epub 2010 Nov 5.
5
Correcting for non-compliance in randomized non-inferiority trials with active and placebo control using structural models.使用结构模型对具有活性对照和安慰剂对照的随机非劣效性试验中的不依从性进行校正。
Stat Med. 2015 Mar 15;34(6):950-65. doi: 10.1002/sim.6392. Epub 2014 Dec 23.
6
A two-stage sample size recalculation procedure for placebo- and active-controlled non-inferiority trials.安慰剂对照和活性药物对照非劣效性试验的两阶段样本量重新计算程序。
Stat Med. 2006 Oct 15;25(19):3396-406. doi: 10.1002/sim.2651.
7
Power and sample size computations in simultaneous tests for non-inferiority based on relative margins.基于相对界值的非劣效性同步检验中的效能与样本量计算
Stat Med. 2006 Apr 15;25(7):1131-47. doi: 10.1002/sim.2359.
8
Sample size determination for comparing several survival curves with unequal allocations.用于比较几个不等分配的生存曲线的样本量确定。
Stat Med. 2004 Jun 15;23(11):1793-815. doi: 10.1002/sim.1771.
9
Blinded sample size reassessment in non-inferiority and equivalence trials.非劣效性和等效性试验中的盲态样本量重新评估。
Stat Med. 2003 Mar 30;22(6):995-1007. doi: 10.1002/sim.1456.
10
Three-arm noninferiority trials with a prespecified margin for inference of the difference in the proportions of binary endpoints.具有预先设定的二元终点比例差异推断界值的三臂非劣效性试验。
J Biopharm Stat. 2013;23(4):774-89. doi: 10.1080/10543406.2013.789893.

引用本文的文献

1
Optimization the design of fixed and group sequential three-arm non-inferiority trials with dichotomous endpoints of risk difference and odds ratio.优化具有风险差异和比值比二分终点的固定和序贯三组非劣效性试验的设计。
Contemp Clin Trials Commun. 2024 Oct 18;42:101383. doi: 10.1016/j.conctc.2024.101383. eCollection 2024 Dec.
2
NONPARAMETRIC TESTING FOR MULTIPLE SURVIVAL FUNCTIONS WITH NON-INFERIORITY MARGINS.具有非劣效性界值的多个生存函数的非参数检验
Ann Stat. 2019 Feb;47(1):205-232. doi: 10.1214/18-AOS1686. Epub 2018 Nov 30.
3
Group-sequential three-arm noninferiority clinical trial designs.
成组序贯三臂非劣效性临床试验设计
J Biopharm Stat. 2017;27(1):1-24. doi: 10.1080/10543406.2016.1148710. Epub 2016 Feb 18.